Comparison of parathyroid imaging with technetium-99m-pertechnetate/sestamibi subtraction, double-phase technetium-99m-sestamibi and technetium-99m-sestamibi SPECT

J Nucl Med. 1997 Jun;38(6):834-9.

Abstract

The ability of 99mTc-pertechnetate/sestamibi subtraction, double-phase 99mTc-sestamibi and 99mTc-sestamibi SPECT imaging to localize abnormal parathyroid tissue was compared.

Methods: Fifty-five consecutive patients had parathyroid imaging before surgery for hyperparathyroidism. Imaging consisted of 99mTc-pertechnetate pinhole images of the neck followed by 99mTc-sestamibi pinhole images of the neck and parallel-hole images of the neck and chest (early images). Within 2.5-4.0 hr later pinhole images of the neck, parallel-hole and SPECT images of the neck and chest were obtained (late images). Nodular foci of increased sestamibi activity were considered abnormal.

Results: The sensitivity for abnormal parathyroid glands by visual comparison of early images and pertechnetate images was 72%-75%, late images and pertechnetate images was 73%-78% and double-phase (early and late) sestamibi images was 62%-65%; computer subtraction of pertechnetate from early images was 71%-74%; and SPECT imaging was 79%. The sensitivity for parathyroid adenomas was 89%-98%, while the sensitivity for hyperplastic parathyroid glands was only 47%-58%.

Conclusion: Late imaging, computer subtraction and SPECT may not be necessary since they provided only marginal improvements on visual comparison of early sestamibi with pertechnetate images. Double-phase sestamibi imaging was less sensitive, so baseline thyroid imaging with pertechnetate is recommended.

Publication types

  • Comparative Study

MeSH terms

  • Adenoma / diagnostic imaging*
  • Evaluation Studies as Topic
  • Female
  • Humans
  • Hyperparathyroidism / diagnostic imaging*
  • Hyperparathyroidism, Secondary / diagnostic imaging*
  • Male
  • Middle Aged
  • Parathyroid Glands / diagnostic imaging
  • Parathyroid Neoplasms / diagnostic imaging*
  • Radiopharmaceuticals*
  • Sensitivity and Specificity
  • Sodium Pertechnetate Tc 99m*
  • Subtraction Technique
  • Technetium Tc 99m Sestamibi*
  • Tomography, Emission-Computed, Single-Photon*

Substances

  • Radiopharmaceuticals
  • Technetium Tc 99m Sestamibi
  • Sodium Pertechnetate Tc 99m